KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBIT Margin (2016 - 2025)

Medpace Holdings (MEDP) has disclosed EBIT Margin for 11 consecutive years, with 21.63% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 173.0% year-over-year to 21.63%, compared with a TTM value of 75.51% through Dec 2025, up 5432.0%, and an annual FY2025 reading of 21.14%, down 5.0% over the prior year.
  • EBIT Margin was 21.63% for Q4 2025 at Medpace Holdings, down from 23.37% in the prior quarter.
  • Across five years, EBIT Margin topped out at 23.37% in Q4 2024 and bottomed at 15.25% in Q2 2021.
  • Average EBIT Margin over 5 years is 19.04%, with a median of 19.39% recorded in 2022.
  • The sharpest move saw EBIT Margin crashed -340bps in 2021, then skyrocketed 585bps in 2024.
  • Year by year, EBIT Margin stood at 17.78% in 2021, then rose by 9bps to 19.39% in 2022, then dropped by -10bps to 17.52% in 2023, then soared by 33bps to 23.37% in 2024, then dropped by -7bps to 21.63% in 2025.
  • Business Quant data shows EBIT Margin for MEDP at 21.63% in Q4 2025, 23.37% in Q4 2024, and 21.05% in Q3 2024.